Zug, Switzerland, March 7, 2017 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it will report its financial results for the full year 2016 on Tuesday, March 14, 2017. Following the announcement, Auris Medical's management team will host a live conference call and webcast at 8:00 am Eastern Time (1:00 pm Central European Time) to discuss the Company's financial results and to provide a general business update.
To participate in this conference call, dial 1-877-280-3488 (USA) or +1-646-254-3372 (International), and enter passcode 7503630. A live webcast of the conference call can be accessed in the Investors section of the Auris Medical website at www.aurismedical.com. A replay will be available approximately two hours following the live call.
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is focused on the Phase 3 development of treatments for acute inner ear hearing loss (AM-111) and for acute inner ear tinnitus (Keyzilen®; AM-101) by way of intratympanic administration with biocompatible gel formulations. In addition, Auris Medical is pursuing intranasal betahistine for Meniere's disease and vestibular vertigo (AM-125) as well as early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol "EARS."
Contact: Cindy McGee, Head of Investor Relations and Corporate Communications, +41 61 201 1350, [email protected]


Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 



